Zomepirac (sodium salt) structure
|
Common Name | Zomepirac (sodium salt) | ||
|---|---|---|---|---|
| CAS Number | 64092-48-4 | Molecular Weight | 313.71100 | |
| Density | N/A | Boiling Point | 470.8ºC at 760 mmHg | |
| Molecular Formula | C15H13ClNNaO3 | Melting Point | N/A | |
| MSDS | Chinese USA | Flash Point | 238.5ºC | |
| Symbol |
GHS06 |
Signal Word | Danger | |
Use of Zomepirac (sodium salt)Zomepirac sodium salt is a pyrrole-acetic acid structurally related to tolmetin sodium; a prostaglandin synthetase inhibitor. |
| Name | sodium,2-[5-(4-chlorobenzoyl)-1,4-dimethylpyrrol-2-yl]acetate |
|---|---|
| Synonym | More Synonyms |
| Description | Zomepirac sodium salt is a pyrrole-acetic acid structurally related to tolmetin sodium; a prostaglandin synthetase inhibitor. |
|---|---|
| Related Catalog |
| Boiling Point | 470.8ºC at 760 mmHg |
|---|---|
| Molecular Formula | C15H13ClNNaO3 |
| Molecular Weight | 313.71100 |
| Flash Point | 238.5ºC |
| Exact Mass | 313.04800 |
| PSA | 62.13000 |
| LogP | 1.51030 |
| InChIKey | SEEXPXUCHVGZGU-UHFFFAOYSA-M |
| SMILES | Cc1cc(CC(=O)[O-])n(C)c1C(=O)c1ccc(Cl)cc1.[Na+] |
| Storage condition | 2-8℃ |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
| Symbol |
GHS06 |
|---|---|
| Signal Word | Danger |
| Hazard Statements | H300-H311-H331 |
| Precautionary Statements | P261-P264-P280-P301 + P310-P311 |
| Personal Protective Equipment | Eyeshields;Faceshields;Gloves;type P2 (EN 143) respirator cartridges |
| Hazard Codes | T |
| Risk Phrases | 23/24/25 |
| RIDADR | UN 2811 6.1/PG 2 |
| RTECS | UX9277000 |
| HS Code | 2933990090 |
| HS Code | 2933990090 |
|---|---|
| Summary | 2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
|
Limitations of hepatocytes and liver homogenates in modelling in vivo formation of acyl glucuronide-derived drug-protein adducts.
J. Pharmacol. Toxicol. Methods 41(1) , 27-32, (1999) The covalent binding of drugs or their metabolites to proteins is of increasing interest in the investigation of the toxicity of these compounds. Recent attention on biological consequences of protein... |
|
|
Regulating the cancer-inducing potential of non-steroidal anti-inflammatory drugs: some lessons from the 1970s and 1980s.
Soc. Sci. Med. 46(1) , 39-51, (1998) This article systematically examines government regulation of medicines in the U.K. and the U.S. with specific reference to carcinogenic risk assessment. By taking four non-steroidal anti-inflammatory... |
|
|
Identification of zomepirac-S-acyl-glutathione in vitro in incubations with rat hepatocytes and in vivo in rat bile.
Drug Metab. Dispos. 31(11) , 1429-36, (2003) Zomepirac (ZP), a nonsteroidal anti-inflammatory drug that was withdrawn from use, is metabolized to zomepirac-1-O-acyl-glucuronide (ZP-1-O-G), a chemically reactive conjugate that has been implicated... |
| Zomax |
| Zomepirac-Na |
| ZOMEPIRAC SODIUM |
| EINECS 264-669-2 |
| sodium 5-(p-chlorobenzoyl)-1,4-dimethylpyrrole-2-acetate |
| Sodium zomepirac |
| Sodium 5-(4-chlorobenzoyl)-1,4-dimethyl-1H-pyrrole-2-acetate |
| Zomepirac sodium salt |
| Zomepirac Na. Dihydrat |
| sodium [5-(4-chlorobenzoyl)-1,4-dimethyl-1H-pyrrol-2-yl]-acetate |
| Zomepirac (sodium salt) |